Unreported Truths β’ 44 implied HN points β’ 07 Mar 26
- A senior FDA medical official who publicly challenged certain mRNA vaccine makers is leaving their post amid intense pressure. Shares of the companies he criticized jumped after the announcement.
- Powerful industry and institutional forces pushed back on criticism and can derail internal reformers. That shows itβs very hard to change drug regulation from inside the current system.
- The market rewarded the outcome, signaling that investors favor moves that help pharmaceutical companies. This dynamic undermines confidence in regulatory independence and efforts to hold companies accountable.